Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Executive Summary

Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.

Advertisement

Related Content

Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy
Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Indivior's Once-Monthly Buprenorphine Clears US FDA With Box Warning, REMS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel